Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)

Company on track to report topline results early in the second quarter of 2026Second planned Data and Safety Monitoring Board (DSMB) meeting evaluated all available safety data for the 82 randomizedNo drug discontinuations, excessive sedation, loss of consciousness, or drug-related…